Table 1. Patients’ characteristics.
| Patients | Overall 433 (%) |
Serum sodium ≥ 136 364 (84) |
Serum sodium ≤ 135 69 (16) |
p |
|---|---|---|---|---|
| Gender | ||||
| Male | 299 (69) | 250 (69) | 49 (71) | 0.77 |
| Female | 134 (31) | 114 (31) | 20 (29) | |
| Age, years | 66 | 66 | 67 | |
| Range | 25−86 | 25−85 | 45−86 | |
| ECOG-PS ≥ 2 | 41 (9) | 33 (9) | 8 (12) | 0.50 |
| ECOG-PS < 2 | 392 (91) | 331 (91) | 61 (88) | |
| Histology | ||||
| Adenocarcinoma | 278 (64) | 238 (65) | 40 (58) | 0.15 |
| Squamous carcinoma | 101 (23) | 80 (22) | 21 (30) | |
| Other | 54 (13) | 46 (13) | 8 (12) | |
| Tumor Stage | ||||
| Stage III | 112 (26) | 96 (26) | 16 (23) | 0.65 |
| Stage IV | 321 (74) | 268 (74) | 53 (77) | |
| EGFR mutation status | ||||
| Wild-type | 388 (90) | 324 (89) | 64 (93) | 0.10 |
| Mutated | 45 (10) | 40 (11) | 5 (7) | |
| Smoking history | ||||
| Former/current smoker | 364 (84) | 302 (83) | 62 (90) | 0.20 |
| Never smokers | 69 (16) | 62 (17) | 7 (10) | |
| Common sites of metastasis | ||||
| Lung | 150 (35) | 123 (34) | 27 (39) | 0.30 |
| Bone | 117 (27) | 102 (28) | 15 (22) | |
| Nervous system | 68 (16) | 62 (17) | 6 (9) | |
| Liver | 54 (13) | 47 (13) | 7 (10) | |
| First-line therapy | ||||
| Platinum-based chemotherapy | 348 (80) | 289 (79) | 59 (86) | 0.18 |
| Non platinum-based | 57 (13) | 48 (13) | 9 (13) | |
| EGFR- tyrosine kinase inhibitor | 28 (7) | 27 (8) | 1 (1) | |
| Response to first-line therapy | ||||
| Partial response | 162 (37)) | 142 (39) | 21 (30) | 0.19 |
| Stable disease | 113 (26) | 91 (25) | 24 (35) | |
| Progression disease | 158 (37) | 135 (37) | 24 (35) |